**eTable 1.** Summary of Inclusion/Exclusion Criteria Used for the Systematic Review

|  |  |  |
| --- | --- | --- |
|   | **Inclusion Criteria** | **Exclusion Criteria** |
| Population | Diagnosis of neovascular/wet AMDAdults ≥18 years of age | Diagnosis of diabetic macular edema or retinal vein occlusion, or mixed population where the neovascular/wet AMD subgroup is not reported separatelyAge <18 y |
| Intervention(s)  | Any of the following using a T&E protocol:Aflibercept (Eylea)Ranibizumab (Lucentis)Bevacizumab (Avastin) | No interventions of interestNo T&E protocol |
| Comparator(s)  | Any, including placebo | No comparator |
| Outcomes  | BCVA gainsNumber of injectionsTreatment interval | No outcomes of interest |
| Study type  | Observational studies (ie, case-control, cohort)Clinical trials (RCT and non-RCT)SLRs with meta-analysis | Nonhuman studies Case series/reportsCommentaries and lettersRecommendations/guidelinesMethods articles/protocolsHypothetical modelsNonsystematic reviews |
| Other | English language onlyStudy size ≥100 eyes overall | Non-English languageStudy size <100 eyes overall |

AMD indicates age-related macular degeneration; BCVA, best-corrected visual acuity; RCT, randomized controlled trial; SLR, systematic literature review; T&E, treat-and-extend.